Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 0.87 |
| ▸ | MMP13 | P45452 | 3/20 | 0.87 |
| ▸ | MMP14 | P50281 | 3/20 | 0.87 |
| ▸ | MMP9 | P14780 | 4/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849438 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3848822 | 0.93 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3848826 | 0.93 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL23752240 | 0.93 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3848459 | 0.91 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3848461 | 0.91 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3855694 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3852436 | 0.89 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3852934 | 0.86 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 | |
| SCHEMBL3850064 | 0.86 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP14MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576222-B2 | N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease | WYETH (US) | 2009-08-18 | — | — | US | claimed |
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-07-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | ADAM17, TPSAB1, ADAM10 | ADAM17 1/4885MMP2 19/4885MMP13 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.